Participated · Seed · Jan 2026

Amy Wines Limited, trading as Ah Wines, was launched by actress and writer Amy Huberman to sell a range of Spanish wines sourced from cooperative vineyards near Valencia. The initial portfolio features a Sauvignon Blanc and a Cava Brut Rosé, both carried nationwide by Tesco and Dunnes Stores. A distinguishing feature is the writable bottle label that lets customers add personal messages. In its first financial year to the end of 2024, the company raised more than €300,000 in equity capital, posted a €52,443 loss, and held €241,651 in cash with €59,043 in stock on hand. The firm’s share capital stood at €300,075 with an additional €49,924 recorded in a share premium account. Key shareholders include Huberman’s ASM Entertainment, Brian O’Driscoll’s ODM, and several beverage and hospitality angels. Management plans to deepen partnerships with Valencian cooperatives to expand its product line, although detailed future rollout timelines were not disclosed.

Participated · Series C · Nov 2017

ImmusanT is a clinical-stage company leveraging its Epitope-Specific Immuno-Therapy (ESIT) platform to develop peptide-based immune therapies for autoimmune diseases. Its lead program, Nexvax2, is a peptide-based therapeutic vaccine in clinical development that has demonstrated safety and relevant bioactivity in multiple Phase 1 studies for celiac disease. The company plans to expand the application of its ESIT platform beyond celiac disease to develop a novel vaccine candidate for type 1 diabetes (T1D), translating insights and clinical experience from its celiac program. ImmusanT received an investment from the JDRF T1D Fund to accelerate this work; terms of the financing were not disclosed. The company describes ESIT as a precision-medicine approach aimed at restoring immune tolerance across a range of diseases. ImmusanT is based in Cambridge, Mass. ImmusanT is developing Nexvax2®, a therapeutic vaccine intended to reprogram T-cells and induce antigen-specific immune tolerance to gluten in celiac disease patients who carry HLA-DQ2.5. The company plans to use the Series C proceeds to fund a randomized Phase II clinical trial of escalating Nexvax2 doses as an adjunct to a gluten-free diet and to demonstrate proof of concept during a gluten challenge. Funds will also support advancement of its diagnostic biomarker program and expansion of its Epitope-Specific Immuno-Therapy (ESIT) platform. ImmusanT positions Nexvax2 as the only therapeutic approach in clinical development that targets the fundamental loss of immune tolerance to gluten. The company notes that approximately 90% of celiac patients carry the HLA-DQ2.5 immune recognition gene and that there is currently no FDA-approved therapeutic for celiac disease. ARCH Venture Partners’ involvement brings two ARCH partners to ImmusanT’s board, and MTS Health Partners advised on the transaction. ImmusanT is focused on restoring immune tolerance to gluten in celiac disease through an epitope-specific immunotherapy platform. Its lead product, Nexvax2, is an adjuvant-free immunotherapy composed of three gluten-derived peptides intended to tolerize patients to gluten. The company completed two Phase 1b studies that demonstrated safety, tolerability and relevant bioactivity, and used those results to design Phase 2 trials. ImmusanT is also developing a companion diagnostic to identify likely responders and a noninvasive, standalone blood-based diagnostic for celiac disease. The $12 million Series B financing announced will fund Phase 2 clinical development and continued diagnostics work. The company says its platform can be applied to other epitope-specific autoimmune diseases. ImmusanT is a Cambridge, Massachusetts–based biotechnology company focused on restoring tolerance to gluten in celiac disease. The company is developing an immunotherapeutic vaccine, Nexvax2®, alongside a companion diagnostic and monitoring tool for celiac disease. It is also developing a proprietary whole-blood functional T-cell test intended as a standalone diagnostic and as a monitoring tool for the therapeutic. ImmusanT plans to use the Series A proceeds to advance Nexvax2 to proof-of-concept and to support its companion diagnostic program. The company expects to initiate its next clinical trial in early 2012. ImmusanT is led by Founder, President and CEO Leslie J. Williams and Scientific Founder and Chief Scientific Officer Dr. Bob Anderson. The Series A financing totaled $20m from Vatera Healthcare Partners LLC.

Participated · Equity · Jun 2015

Melinta Therapeutics focuses on discovering, developing, and commercializing antibiotics that address life-threatening bacterial infections, particularly those caused by drug-resistant ESKAPE pathogens. Its lead product, Baxdela (delafloxacin), has U.S. FDA approval for the treatment of acute bacterial skin and skin structure infections (ABSSSI) and received priority review under the GAIN Act. The company plans to expand Baxdela into additional indications, including community-acquired bacterial pneumonia, and is leveraging Nobel Prize-winning science to create an entirely new class of antibiotics against multi- and extremely-drug-resistant organisms. Headquartered in New Haven, Connecticut, with offices in Lincolnshire, Illinois, Melinta is backed by investors such as Vatera Healthcare Partners and Malin Corporation plc. The firm positions itself as a key player in combating the global public-health crisis of antibiotic resistance. This financing provides the capital needed to commercialize Baxdela’s first indication and support further clinical studies while retiring earlier debt. The structure of the financing—with a mix of debt and equity and cash-sparing repayment terms—helps preserve the company’s ownership structure and financial flexibility.

Led · Series D · Nov 2012

Pearl Therapeutics develops combination therapies for highly prevalent respiratory diseases, primarily chronic obstructive pulmonary disease (COPD) and asthma. Its lead candidate, PT003, combines glycopyrrolate (a long-acting muscarinic antagonist, LAMA) and formoterol fumarate (a long-acting beta-2 agonist, LABA) delivered via a metered dose inhaler (HFA MDI). The company intends to use the newly raised capital to start Phase 3 trials for PT003. Pearl was founded in 2006 and is led by CEO Chuck Bramlage. The business recently completed a $65M Series D financing to fund clinical development. It focuses on inhaled combination therapies aimed at addressing unmet needs in chronic respiratory care. Pearl Therapeutics develops clinically differentiated combination therapies targeting highly prevalent chronic respiratory diseases, with a lead product, PT003, a combination bronchodilator for COPD. The company is based in Redwood City, CA. The $69M Series C financing will enable Pearl to complete the entire Phase 2b program for PT003. After concluding Phase 2b, Pearl expects to initiate Phase 3 clinical trials in late 2012. The financing brings the company’s total funding to $102.5M raised since 2007. Management changes tied to the round include a new board member and a board observer from the lead investor. Pearl Therapeutics is a Redwood City, CA–based developer of therapies for chronic respiratory diseases. Its lead product is PT003, a combination therapeutic for the treatment of chronic obstructive pulmonary disease (COPD). The company announced a $15M financing from existing investors Clarus Ventures, New Leaf Venture Partners and 5AM Ventures. The capital was raised through a convertible loan facility that will convert to Pearl equity at the time of a Series C financing. Pearl will use the new capital to initiate a Phase 2b clinical trial of PT003. The company also promoted William Picht, Jr., to vice president, finance and administration. Pearl Therapeutics develops inhaled drugs targeting respiratory diseases including COPD and asthma. The company licensed a particle-based technology from Nektar Therapeutics to improve inhaled drug targeting and lung distribution and reduce side effects. It plans to expand its product line using newly secured financing. Pearl recently raised $8 million in venture debt from Oxford Finance and Silicon Valley Bank to support that expansion. The company previously raised $33.5 million over two funding rounds, including an $18 million investment in July 2008, with backers such as New Leaf Ventures, 5AM Ventures, and Clarus Ventures. Pearl has not disclosed whether its products are in clinical trials or when they might reach the commercial market. Pearl Therapeutics is a Redwood City, Calif.-based biopharmaceutical company. The company increased its first round to $33.5 million following an additional $18 million investment. New investor Nektar Therapeutics joined prior backers Clarus Ventures, New Leaf Ventures and 5AM Ventures in the raise. Including debt financing, Pearl Therapeutics now has $36.4 million. The article does not disclose product details, operating metrics, or planned use of proceeds.